Kavar Capital Partners LLC acquired a new stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 150 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Horan Capital Advisors LLC. acquired a new position in GW Pharmaceuticals PLC- in the first quarter valued at about $25,000. Exane Derivatives acquired a new position in GW Pharmaceuticals PLC- in the first quarter valued at about $28,000. TCG Advisors LP acquired a new position in GW Pharmaceuticals PLC- in the first quarter valued at about $29,000. Institutional & Family Asset Management LLC acquired a new position in GW Pharmaceuticals PLC- in the first quarter valued at about $31,000. Finally, Duncker Streett & Co. Inc. acquired a new position in GW Pharmaceuticals PLC- in the first quarter valued at about $34,000. Institutional investors and hedge funds own 78.92% of the company’s stock.
In related news, insider Douglas B. Snyder sold 3,756 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $13.88, for a total transaction of $52,133.28. Following the completion of the transaction, the insider now directly owns 79,164 shares of the company’s stock, valued at $1,098,796.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott M. Giacobello sold 4,224 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $14.52, for a total value of $61,332.48. The disclosure for this sale can be found here. Insiders have sold 378,288 shares of company stock valued at $5,710,525 over the last three months. Insiders own 3.60% of the company’s stock.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative return on equity of 38.09% and a negative net margin of 101.45%. The company had revenue of $72.04 million during the quarter, compared to analysts’ expectations of $37.28 million. During the same period in the prior year, the firm earned ($0.25) earnings per share. GW Pharmaceuticals PLC-‘s revenue for the quarter was up 2096.3% compared to the same quarter last year. As a group, research analysts forecast that GW Pharmaceuticals PLC- will post -3.84 EPS for the current fiscal year.
GWPH has been the subject of a number of research analyst reports. Morgan Stanley boosted their target price on GW Pharmaceuticals PLC- to $238.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Jaffray Companies upped their price objective on GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. JPMorgan Chase & Co. raised GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research report on Wednesday, May 8th. BidaskClub cut GW Pharmaceuticals PLC- from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 24th. Finally, Cowen reaffirmed a “buy” rating and set a $200.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Friday, July 26th. Two analysts have rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- has a consensus rating of “Buy” and a consensus target price of $212.70.
GW Pharmaceuticals PLC- Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
See Also: Neutral Rating
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.